Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia

Research output: Contribution to journal › Editorial › Academic › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	547-550
Number of pages	4
Journal	Journal of thoracic oncology
Volume	19
Issue number	4
DOIs	https://doi.org/10.1016/j.jtho.2024.01.017
Publication status	Published - 1 Apr 2024
Externally published	Yes

Access to Document

@article{8fc95dba8a1b45cdbf0848a67eae9cb8,

title = "Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia",

author = "Illaa Smesseim and Paul Baas",

year = "2024",

month = apr,

day = "1",

doi = "10.1016/j.jtho.2024.01.017",

language = "English",

volume = "19",

pages = "547--550",

journal = "Journal of thoracic oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "4",

}

TY - JOUR

T1 - Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia

AU - Smesseim, Illaa

AU - Baas, Paul

PY - 2024/4/1

Y1 - 2024/4/1

UR - http://www.scopus.com/inward/record.url?scp=85190081298&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2024.01.017

DO - 10.1016/j.jtho.2024.01.017

M3 - Editorial

C2 - 38582547

SN - 1556-0864

VL - 19

SP - 547

EP - 550

JO - Journal of thoracic oncology

JF - Journal of thoracic oncology

IS - 4

ER -